What is Zacks Research’s Estimate for IRWD FY2024 Earnings?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Stock analysts at Zacks Research decreased their FY2024 earnings estimates for shares of Ironwood Pharmaceuticals in a research report issued to clients and investors on Thursday, November 28th. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earnings of $0.08 per share for the year, down from their prior estimate of $0.14. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.08 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.17 EPS and Q3 2026 earnings at $0.13 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm had revenue of $91.60 million during the quarter, compared to the consensus estimate of $91.22 million. During the same period in the previous year, the firm earned $0.12 EPS. The business’s revenue was down 19.4% on a year-over-year basis.

A number of other equities analysts also recently issued reports on IRWD. Craig Hallum dropped their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Capital One Financial cut shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Wells Fargo & Company lowered their target price on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. Finally, StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Ironwood Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.40.

Ironwood Pharmaceuticals Stock Up 2.8 %

Ironwood Pharmaceuticals stock opened at $3.62 on Monday. Ironwood Pharmaceuticals has a 52-week low of $3.26 and a 52-week high of $15.70. The company has a market cap of $579.31 million, a P/E ratio of -120.67 and a beta of 0.47. The business has a 50-day simple moving average of $4.11 and a two-hundred day simple moving average of $5.16.

Insider Buying and Selling

In related news, CFO Sravan Kumar Emany sold 11,001 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the transaction, the chief financial officer now directly owns 309,572 shares of the company’s stock, valued at approximately $1,263,053.76. The trade was a 3.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 12.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC grew its stake in Ironwood Pharmaceuticals by 55.1% during the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 2,345 shares in the last quarter. KBC Group NV boosted its holdings in shares of Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,198 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Ironwood Pharmaceuticals by 344.1% during the second quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 8,156 shares in the last quarter. First Dallas Securities Inc. bought a new stake in shares of Ironwood Pharmaceuticals in the second quarter worth about $73,000. Finally, Diversified Trust Co purchased a new stake in shares of Ironwood Pharmaceuticals in the third quarter worth about $52,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.